by Clinical Neuropsychologist Online | Wednesday, July 22, 2026 | Dementia
Abstract INTRODUCTION We evaluated the prognostic value of baseline plasma phosphorylated tau 217 ratio (%p-tau217) for predicting long-term progression in cognitively unimpaired (CU) older adults. METHODS We analyzed 982 community-dwelling individuals followed...
by Clinical Neuropsychologist Online | Tuesday, July 21, 2026 | Dementia
Abstract INTRODUCTION Declining nicotinamide adenine dinucleotide (NAD+) may elevate risk of Alzheimer’s disease. METHODS We conducted a 12-week double-blind, randomized, placebo-controlled pilot study to evaluate the safety, tolerability, and preliminary...
by Clinical Neuropsychologist Online | Monday, July 20, 2026 | Dementia
Abstract INTRODUCTION Although cerebrospinal fluid (CSF) biomarkers reflect neurodegeneration in Alzheimer’s disease (AD), it remains unclear whether these biomarkers track neurodegeneration in early-onset Alzheimer’s disease (EOAD). METHODS In 80 EOAD...
by Clinical Neuropsychologist Online | Monday, July 20, 2026 | Dementia
Abstract People with dementia are at increased risk of hospitalization compared to individuals without dementia, yet the efficacy of psychosocial and healthcare interventions in reducing hospitalization is unclear. We conducted an umbrella review examining the effects...
by Clinical Neuropsychologist Online | Monday, July 20, 2026 | Dementia
Abstract Evidence linking sleep and circadian disruptions to the course of dementias, particularly Alzheimer’s disease, has expanded. Such alterations are detectable from preclinical stages and parallel the disease progression. Assessing and managing sleep and...
by Clinical Neuropsychologist Online | Sunday, July 19, 2026 | Dementia
Abstract INTRODUCTION Neurodegenerative disorders, including amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), limbic-predominant age-related TDP-43 encephalopathy (LATE), and Alzheimer’s disease (AD) are associated with TAR DNA-binding protein...
